Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Oesophageal cancer, drawn from the whole corpus: 105 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Late presentation.
Background: Barrett's oesophagus. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Squamous cell carcinoma lacks targets beyond EGFR/HER3.
Most patients present with advanced disease; no Western screening for squamous cancer and only trial-stage non-endoscopic screening for Barrett's.
Background: Barrett's oesophagus. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Adjuvant nivolumab improves DFS but not significantly OS; who truly needs it (PD-L1, ctDNA) is unknown.
Squamous cell carcinoma has no validated molecular targets beyond PD-1 and, since 2026, EGFR/HER3 antigen delivery.
PD-L1-negative tumours derive little from chemo-immunotherapy; alternatives are lacking.
Whether adding PD-1 blockade to definitive chemoradiation improves cure remains unproven pending KEYNOTE-975 and SKYSCRAPER-07.
Organ preservation requires intensive surveillance and salvage surgery capacity that many centres lack.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Oesophagectomy carries high morbidity; centralisation and minimally invasive approaches are unevenly adopted.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 42 changes by month →When this page itself was last checked or edited.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Co-primary endpoints including OS met (July 2026); numbers pending.
PFS 12.